Overview

• Nuvama maintained a Buy rating on Divi’s Laboratories with a target price of Rs 7,110, implying roughly 15% upside.
• Analysts say Divi is working on two to three ingredients for Eli Lilly’s oral GLP‑1 candidate Orforglipron, with initial capacity already in place.
• Orforglipron delivered positive Phase III results and Eli Lilly is preparing regulatory submissions with approval targeted around 2026.
• Nuvama estimates about $60 million in revenue at current capacity for Divi, with potential to scale to $200–300 million at peak, though timing and size remain uncertain.
• The brokerage cites industry expectations for Orforglipron peak sales of $15–40 billion and a corresponding CMO opportunity of roughly $500 million–$1.5 billion, while Business Today reports Lilly has built a $550 million pre‑launch inventory.